These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30203314)

  • 21. Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
    Einsiedler M; Kremer L; Fleury M; Collongues N; De Sèze J; Bigaut K
    J Neurol; 2022 Sep; 269(9):4846-4852. PubMed ID: 35430690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate mofetil therapy in uveitis: analysis of eight cases in a tertiary ophthalmic care centre in India.
    Rathore VM; Agrawal R; Chaudhary SP; Biswas J
    Int Ophthalmol; 2009 Apr; 29(2):117-22. PubMed ID: 18080093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
    Chartier N; Epstein J; Soudant M; Dahan C; Michaud M; Pittion-Vouyovitch S; Guillemin F; Debouverie M; Mathey G
    Eur J Neurol; 2018 Dec; 25(12):1439-1445. PubMed ID: 29996003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS.
    Bosma L; Kragt JJ; Polman CH; Uitdehaag BM
    Mult Scler; 2013 Mar; 19(3):326-33. PubMed ID: 22907939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
    Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
    Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapses and disability accumulation in progressive multiple sclerosis.
    Paz Soldán MM; Novotna M; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Jan; 84(1):81-8. PubMed ID: 25398229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
    Pawate S; Wang L; Song Y; Sriram S
    J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study.
    Li S; Ren H; Xu Y; Xu T; Zhang Y; Yin H; Zhang W; Li J; Ren X; Fang F; Li W; Zhu Y; Peng B; Wang J; Zhong Y; Cui L
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32170045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D
    Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis.
    Hedayatfar A; Falavarjani KG; Soheilian M; Elmi Sadr N; Modarres M; Parvaresh MM; Naseripour M; Rohani M; Almasi M; Chee SP
    Ocul Immunol Inflamm; 2017 Jun; 25(3):308-314. PubMed ID: 27379567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The search for responsive clinical endpoints in primary progressive multiple sclerosis.
    Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM
    Mult Scler; 2009 Jun; 15(6):715-20. PubMed ID: 19383646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.
    Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G
    Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.